The global epigenetics market size was valued at USD 5.25 billion in 2017. It is estimated to register a CAGR of 19.7% during the forecast period. Increasing prevalence of cancer and other chronic diseases along with rising geriatric population is poised to bolster the growth of the market.
Presence of organizations such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) is positively influencing the growth of the market. These organizations are promoting funding and support to R&D and product development exercises pertaining to field of epigenetics. NIH funds epigenetics research through common fund epigenomics program, which actively supports new epigenetic research worldwide.
Rising need to understand epigenetic modifications at molecular level and development of therapeutic solutions are likely to motivate these organizations to fund research and development programs. In addition, endeavors such as the Epidemiology and Genomics Research Program (EGRP) grants incentives to research activities that are working towards understanding of cancer causes and their related outcomes.
According to NCI, the estimated number of cancer deaths in the U.S. is 163.5 per 100,000 men and women per year. The International Cancer Genome Consortium (ICGC) is focusing on obtaining genomic description, epigenomic changes, and transcriptomic changes in different types of tumors.
The Encyclopedia of DNA Elements (ENCODE) project was launched by the U.S. national human genome research institute with an objective to identify all the human genome sequence functional elements. The International Human Epigenome Consortium (IHEC), built by NIH is also involved in development of epigenomic data generation and analysis, which can be made useful for epigenomic researchers. Majorly, epigenetics research is focusing on identification of treatment options for various types of tumors.
Based on products, the reagents dominated the market in 2017. Histone and DNA modifiers are the major types of reagents used for epigenetics. Some of the common epigenetic reagents are antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid analysis reagents, and buffers. PyroMark Q24 is one of the advanced reagents featuring advanced pyrosequencing chemistry to provide even better real - time sequence - based detection and quantification than before.
Existence of a number of technology platforms facilitates analysis at gene, protein, or cellular levels, which encourages innovation in the global marketplace. Polymerase chain reaction (PCR) has helped establish a platform for genomic. Gene regulation is impacted by epigenetic factors such as chromatin structure, DNA methylation, and non - coding RNAs. The life sciences and analytical tools market is greatly influenced by wide use of reagents.
The kits segment, on the other hand, is expected to post the highest CAGR during the forecast period. Ready - to - use kits are manufactured by many biotechnology companies for detection of epigenetic modifications. Kits available in the market range from kits for nucleic acid purification, analysis of DNA methylation status, and detection of histone modifications by various enzymes to kits for chromatin immunoprecipitation. Epigenetic diagnostic kits are used for diagnosis of disorders due to epigenetic modifications in early stages and during treatment to check efficacy of therapeutics. They work on basis of immunoprecipitation by involvement of modification - specific monoclonal antibodies.
The market, on the basis of technology, can be divided into DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, and chromatin structures. DNA methylation accounted for the leading share in the epigenetics market in 2017. DNA methylation is covalent addition of a methyl group in cytosine ring, which leads to inhibition of transcription. Sensitive bisulphite modification followed by PCR is called methylation sensitive PCR (MSP).
Real time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are variations of MSP. Currently, quantitative methods such as allele - specific bisulphite sequencing, southern - based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI - TOF MS are also useful for DNA methylation. Advancements in technologies are increasingly enabling assessment of locus - specific DNA methylation on genome wide scale.
Histone Acetylation is expected to experience the fastest growth over the forecast period owing to its enhanced efficacy due to introduction of novel mechanisms. It is enzymatic incorporation of an acetyl group to lysine residues. Histone acetylation is involved in control of cellular processes such as gene silencing, chromatin transcription and dynamics, progression of cell cycle, differentiation, apoptosis, DNA replication, neuronal repression, nuclear import, and DNA repair. Enzymes involved in histone acetylation are Histone Acetyl Transferases (HATs) and enzymes involved in deacetylation are histone deacetylases (HDACs).
Oncology was the leading revenue contributor in the global market, accounting for approximately 70.0% of the market in 2017. Increasing prevalence of cancer worldwide along with rising cases of deaths due to the disease is contributing to the growth of the segment. Moreover, introduction of new products and potential commercialization of products currently in the pipeline in the near future are projected to trigger the growth of the segment.
Hypermethylation and epigenetic silencing are known as epimutations, occurring due to epigenetic changes. Epimutations have been known to be involved in etiology of cancers. Extensive R&D is going on for detecting epimutations, specifically related to silencing of tumor suppressor genes and activation of oncogenes. Unlike regular mutations, epimutations are reversible in nature.
Non - oncology is anticipated to register a higher CAGR during the forecast period. The growth of the segment can be attributed to rigorous R&D initiatives undertaken by private institutions and biopharmaceutical companies for identification of epigenetic markers related to these disorders.Epigenetic modifications are being proved to be the base of several non - oncology disorders such as metabolic disorders, neurodegenerative disorders, and infectious diseases. Extensive research is undertaken by private institutions and biopharmaceutical companies for detection of biomarkers for drug development.
North America was at the forefront of the market, with a share of about 40.0% in 2017. Governments in the region are encouraging ongoing research activities on epigenetics by funding them. Besides this, presence of advanced healthcare facilities and continual advancements in diagnostic procedures are stimulating the growth of the regional market. The market in North America is also estimated to be driven by growing geriatric population and high acceptance for technologically advanced facilities.
In addition, common fund supported programs in the U.S. are expected to support epigenetic research activities, covering diversified range of diseases including oncology and non - oncology diseases such as cardiovascular, metabolic, inflammatory, and other diseases.
Asia Pacific is estimated to witness the fastest growth over the forecast period owing to rising disposable income, high unmet clinical needs of patients, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China.Asia Pacific is the most promising destination for market players due to increasing cases of various types of cancers in this region.
Growth of geriatric population is expected to further escalate market growth . R&D initiatives related to analysis of epigenetic base in various diseases are increasing in this region. EpiGen Research Consortium based in the U.K. has extended its research facility in Singapore for research on chronic diseases such as diabetes and obesity.
Key players in this industry are Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; and Novartis AG. Some of the major players are focusing on expanding their businesses in developing regions to increase their market share.
In addition, they are adopting strategies such as mergers & acquisitions and development of new products. For instance, in March 2015, Illumina, Inc. collaborated with Merck Serono to develop a universal next - sequencing - based oncology diagnostic.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2018 - 2025
Revenue in USD Million & CAGR from 2014 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, China, Japan, India, Brazil, Mexico, South Africa,
Revenue, company share, competitive landscape, growth factors, trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub - segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global epigenetics market report on the basis of product, technology, application, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
ChIP sequencing kit
Whole Genomic Amplification kit
Bisulfite Conversion kit
RNA sequencing kit
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Large non - coding RNA
Application Outlook (Revenue, USD Million, 2014 - 2025)
Non - oncology
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."